These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 22870802)

  • 21. Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis.
    Taneja A; Desrivot J; Diderichsen PM; Blanqué R; Allamasey L; Fagard L; Fieuw A; Van der Aar E; Namour F
    Clin Pharmacokinet; 2019 Sep; 58(9):1175-1191. PubMed ID: 30953319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel investigational agents for the treatment of scleroderma.
    McMahan ZH; Wigley FM
    Expert Opin Investig Drugs; 2014 Feb; 23(2):183-98. PubMed ID: 24261610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of a Potent, Selective, and Orally Bioavailable Tool Compound for Probing the Role of Lysophosphatidic Acid Type 2 Receptor Antagonists in Fibrotic Disorders.
    Armani E; Rizzi A; Iotti N; Saccani F; Di Lascia MR; Tigli L; Pappani A; Marchini G; Murgo A; Capelli AM; Delcanale M; Puccini P; Villetti G; Civelli M; Beato C; Giuliani M; Mundi C; Murarolli F; Pagano M; Raveglia LF; Remelli R; Amari G
    J Med Chem; 2023 Apr; 66(8):5622-5656. PubMed ID: 37017110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigational drugs for idiopathic pulmonary fibrosis.
    Varone F; Montemurro G; Macagno F; Calvello M; Conte E; Intini E; Iovene B; Leone PM; Mari PV; Richeldi L
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1019-1031. PubMed ID: 28777013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. From lung injury to fibrosis.
    Ley K; Zarbock A
    Nat Med; 2008 Jan; 14(1):20-1. PubMed ID: 18180715
    [No Abstract]   [Full Text] [Related]  

  • 26. [Future prospects in the treatment of idiopathic pulmonary fibrosis].
    Morell F; Villar A
    Arch Bronconeumol; 2012 Oct; 48 Suppl 2():13-5. PubMed ID: 23116903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Idiopathic pulmonary fibrosis: in search of an effective treatment].
    Selman M; Navarro C; Gaxiola M
    Arch Bronconeumol; 2005 Dec; 41 Suppl 5():15-20. PubMed ID: 17125702
    [No Abstract]   [Full Text] [Related]  

  • 28. Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA
    Cheng PTW; Kaltenbach RF; Zhang H; Shi J; Tao S; Li J; Kennedy LJ; Walker SJ; Shi Y; Wang Y; Dhanusu S; Reddigunta R; Kumaravel S; Jusuf S; Smith D; Krishnananthan S; Li J; Wang T; Heiry R; Sum CS; Kalinowski SS; Hung CP; Chu CH; Azzara AV; Ziegler M; Burns L; Zinker BA; Boehm S; Taylor J; Sapuppo J; Mosure K; Everlof G; Guarino V; Zhang L; Yang Y; Ruan Q; Xu C; Apedo A; Traeger SC; Cvijic ME; Lentz KA; Tirucherai G; Sivaraman L; Robl J; Ellsworth BA; Rosen G; Gordon DA; Soars MG; Gill M; Murphy BJ
    J Med Chem; 2021 Nov; 64(21):15549-15581. PubMed ID: 34709814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Idiopathic pulmonary fibrosis and systemic sclerosis: pathogenic mechanisms and therapeutic interventions.
    Mattoo H; Pillai S
    Cell Mol Life Sci; 2021 Jul; 78(14):5527-5542. PubMed ID: 34145462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lysophosphatidic acid-induced interleukin expression by human periosteum-derived cells.
    Mansell JP
    Bone; 2013 Jul; 55(1):269. PubMed ID: 23435189
    [No Abstract]   [Full Text] [Related]  

  • 31. Antioxidant therapy for idiopathic pulmonary fibrosis. A promising therapeutic prospect.
    Tomioka H
    Sarcoidosis Vasc Diffuse Lung Dis; 2009 Jul; 26(2):83-4. PubMed ID: 20560287
    [No Abstract]   [Full Text] [Related]  

  • 32. Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis.
    Distler JH; Feghali-Bostwick C; Soare A; Asano Y; Distler O; Abraham DJ
    Arthritis Rheumatol; 2017 Feb; 69(2):257-267. PubMed ID: 27636741
    [No Abstract]   [Full Text] [Related]  

  • 33. Single-cell RNA sequencing identifies G-protein coupled receptor 87 as a basal cell marker expressed in distal honeycomb cysts in idiopathic pulmonary fibrosis.
    Heinzelmann K; Hu Q; Hu Y; Dobrinskikh E; Ansari M; Melo-Narváez MC; Ulke HM; Leavitt C; Mirita C; Trudeau T; Saal ML; Rice P; Gao B; Janssen WJ; Yang IV; Schiller HB; Vladar EK; Lehmann M; Königshoff M
    Eur Respir J; 2022 Jun; 59(6):. PubMed ID: 35604813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cooperative activation of divergent pathways by LPAR1 and LPAR2 receptors in fibrotic signaling.
    Reddy MA; Natarajan R
    Am J Physiol Renal Physiol; 2021 Mar; 320(3):F322-F324. PubMed ID: 33491561
    [No Abstract]   [Full Text] [Related]  

  • 35. Challenges in translating preclinical studies to effective drug therapies in idiopathic pulmonary fibrosis.
    Thannickal VJ; Roman J
    Am J Respir Crit Care Med; 2010 Mar; 181(6):532-3. PubMed ID: 20208038
    [No Abstract]   [Full Text] [Related]  

  • 36. Regulation of Lysophosphatidic Acid Metabolism and Signaling by Lipoproteins.
    Morris AJ; Smyth SS
    Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2029-30. PubMed ID: 27655776
    [No Abstract]   [Full Text] [Related]  

  • 37. [Molecular targeted therapy for respiratory diseases].
    Yamasawa H; Sugiyama Y
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():597-601. PubMed ID: 23513909
    [No Abstract]   [Full Text] [Related]  

  • 38. GPR84: an immune response dial?
    Wojciechowicz ML; Ma'ayan A
    Nat Rev Drug Discov; 2020 Jun; 19(6):374. PubMed ID: 32494048
    [No Abstract]   [Full Text] [Related]  

  • 39. Using Lung MRI and Elastic Registration to Assess Pulmonary Fibrosis.
    Biederer J
    Radiology; 2019 May; 291(2):493-494. PubMed ID: 30848699
    [No Abstract]   [Full Text] [Related]  

  • 40. "Chemical genetics" speeds up drug discovery.
    Vastag B
    J Natl Cancer Inst; 1998 Dec; 90(23):1771-2. PubMed ID: 9839516
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.